NCT01531673 - Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation | Biotech Hunter

Enrollment

194

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions

Cystic Fibrosis

Interventions

DRUG

VX-661

DRUG

Ivacaftor

DRUG

Placebo matched to VX-661

DRUG

Placebo matched to ivacaftor

Trial Locations (36)

Unknown

Vertex Investigational Site, Birmingham

Vertex Investigational Site, Oakland

Vertex Investigational Site, Boise

Vertex Investigational Site, Chicago

Vertex Investigational Site, Boston

Vertex Investigational Site, Grand Rapids

Vertex Investigational Site, Kansas City

Vertex Investigational Site, Long Branch

Vertex Investigational Site, New Hyde Park

Vertex Investigational Site, Chapel Hill

Vertex Investigational Site, Cincinnati

Vertex Investigational Site, Columbus

Vertex Investigational Site, Oklahoma City

Vertex Investigational Site, Hershey

Vertex Investigational Site, Pittsburgh

Vertex Investigational Site, Charleston

Vertex Investigational Site, Salt Lake City

Vertex Investigational Site, Burlington

Vertex Investigational Site, Seattle

Vertex Investigational Site, Calgary

Vertex Investigational Site, Vancouver

Vertex Investigational Site, Halifax

Vertex Investigational Site, Toronto

Vertex Investigational Site, Erlangen

Vertex Investigational Site, Frankfurt am Main

Vertex Investigational Site, Hanover

Vertex Investigational Site, Cologne

Vertex Investigational Site, Berlin

Vertex Investigational Site, Bochum

Vertex Investigational Site, Jena

Vertex Investigational Site, Munich

Vertex Investigational Site, Cambridge

Vertex Investigational Site, London

Vertex Investigational Site, Manchester

Vertex Investigational Site, Southhampton

Vertex Investigational Site, Cardiff

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY